Synthesis of Fenthion Sulfoxide and Fenoxon Sulfoxide Enantiomers:  Effect of Sulfur Chirality on Acetylcholinesterase Activity

• Published in: Chemical research in toxicology 2007-02, Vol.20 (2), p.257-262
• Main Authors: Gadepalli, Rama Sarma V. S, Rimoldi, John M, Fronczek, Frank R, Nillos, Mae, Gan, Jay, Deng, Xin, Rodriguez-Fuentes, Gabriela, Schlenk, Daniel
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase - chemistry; Acetylcholinesterase - drug effects; Crystallography, X-Ray; Enzyme Activation - drug effects; Fenthion - analogs & derivatives; Fenthion - chemical synthesis; Fenthion - chemistry; Fenthion - pharmacology; Models, Molecular; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Sulfoxides - chemical synthesis; Sulfoxides - chemistry; Sulfoxides - pharmacology
• ISSN: 0893-228X; 1520-5010
• DOI: 10.1021/tx060153l

Earlier reports have demonstrated that recombinant flavin-containing monooxygenase 1 (FMO1) catalyzes the oxidation of the organophosphate pesticide fenthion to (+)-fenthion sulfoxide in a stereoselective fashion. In order to elucidate the absolute configuration of the sulfoxide metabolite produced, we established an efficient synthesis of both enantiomers of fenthion sulfoxide, which were transformed into chiral fenoxon sulfoxides using a two-step protocol. The use of chiral oxidants, namely, N-(phenylsulfonyl)(3,3-dichlorocamphoryl) oxaziridines, afforded enantioenriched fenthion sulfoxides with high ee (>82%) from the parent sulfide. Single recrystallizations afforded chiral fenthion sulfoxides with >99% ee, measured by chiral HPLC analysis. The absolute configuration of the (+)-sulfoxide generated from fenthion metabolism by FMO1 was determined to be (R)-(+)-fenthion sulfoxide, confirmed by X-ray crystallographic analysis of the (S)-(−)-antipode. Inhibition of human recombinant (hrAChE) and electric eel (eeAChE) acetylcholinesterase were assayed with fenthion, fenoxon, and the racemates and enantiomers of fenthion sulfoxide and fenoxon sulfoxide. Results revealed stereoselective inhibition with (R)-(+)-fenoxon sulfoxide when compared with that of (S)-(−)-fenoxon sulfoxide (IC50 of 6.9 and 6.5 μM vs 230 and 111 μM in hrAChE and eeAChE, respectively). Fenthion sulfoxide (R or S enantiomers) did not present anti-AChE properties. Although the stereoselective sulfoxidation of fenthion to (R)-(+)-fenthion sulfoxide by FMO represents a detoxification pathway, the results of this study support the notion that subsequent oxidative desulfuration of (R)-(+)-fenthion sulfoxide (in vivo) may represent a critical bioactivation pathway, resulting in the production of (R)-(+)-fenoxon sulfoxide, a potent AChE inhibitor.